Cargando…

Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears

The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization and inter-observer variability. Deep learning (DL) can process medical image data and provides data-driven clas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eckardt, Jan-Niklas, Middeke, Jan Moritz, Riechert, Sebastian, Schmittmann, Tim, Sulaiman, Anas Shekh, Kramer, Michael, Sockel, Katja, Kroschinsky, Frank, Schuler, Ulrich, Schetelig, Johannes, Röllig, Christoph, Thiede, Christian, Wendt, Karsten, Bornhäuser, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727290/ https://www.ncbi.nlm.nih.gov/pubmed/34497326 http://dx.doi.org/10.1038/s41375-021-01408-w

Ejemplares similares

Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms
por: Ruhnke, Leo, et al.
Publicado: (2021)

Reinforcement Learning for Precision Oncology
por: Eckardt, Jan-Niklas, et al.
Publicado: (2021)

Semi-supervised learning in cancer diagnostics
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
por: Sockel, Katja, et al.
Publicado: (2022)

Deep sequencing in CD34(+) cells from peripheral blood enables sensitive detection of measurable residual disease in AML
por: Stasik, Sebastian, et al.
Publicado: (2022)

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
por: Alakel, Nael, et al.
Publicado: (2017)

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
por: Teipel, Raphael, et al.
Publicado: (2022)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

The prevalence of extramedullary acute myeloid leukemia detected by (18)FDG-PET/CT: final results from the prospective PETAML trial
por: Stölzel, Friedrich, et al.
Publicado: (2020)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia
por: Kunadt, Desiree, et al.
Publicado: (2020)

Clonal hematopoiesis and its emerging effects on cellular therapies
por: von Bonin, Malte, et al.
Publicado: (2021)

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
por: Stasik, Sebastian, et al.
Publicado: (2022)

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
por: Eckardt, Jan-Niklas, et al.
Publicado: (2021)

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
por: Georgi, Julia-Annabell, et al.
Publicado: (2023)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
por: Kayser, S, et al.
Publicado: (2016)

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34(+)CD123(+) Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia
por: Schmidt, Johannes R., et al.
Publicado: (2018)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP
por: Georgi, Julia-Annabell, et al.
Publicado: (2023)

Klonale Hämatopoese – Bedeutung für die Zelltherapie
por: Teipel, Raphael, et al.
Publicado: (2022)

T-cell receptor-α repertoire of CD8+ T cells following allogeneic stem cell transplantation using next-generation sequencing
por: Link-Rachner, Cornelia S., et al.
Publicado: (2019)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
por: Oelschlaegel, U, et al.
Publicado: (2016)

Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors
por: Parmentier, Stefani, et al.
Publicado: (2020)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
por: Sockel, Katja, et al.
Publicado: (2023)

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
por: Platzbecker, U, et al.
Publicado: (2012)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia
por: Vucinic, Vladan, et al.
Publicado: (2021)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia
por: Kuželová, Kateřina, et al.
Publicado: (2022)

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants
por: Stasik, S., et al.
Publicado: (2018)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_02qpa01o2562353rih0938mt7g